

Paper No. \_\_\_\_\_  
Filed: May 9, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner,

v.

ICOS CORPORATION,  
Patent Owner.

---

Case No. IPR2017-00323  
Patent No. 6,943,166

---

**PETITIONER MYLAN PHARMACEUTICALS INC.'S  
UPDATED LIST OF EXHIBITS**

**LIST OF EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
1001	Pullman, W. E., <i>et al.</i> , <i>Compositions Comprising Phosphodiesterase [Inhibitors] for the Treatment of Sexual Dysfunction</i> , U.S. Patent No. 6,943,166 (filed on April 26, 2000; issued September 13, 2005)
1002	Declaration of Dr. George Grass, Pharm.D., Ph.D.
1003	<i>Curriculum vitae</i> of Dr. George Grass
1004	Declaration of Dr. Muta Issa, M.D.
1005	<i>Curriculum vitae</i> of Dr. Muta Issa
1006	File History for U.S. Patent No. 6,943,166
1007	Daugan, A.C-M., <i>Use of cGMP-Phosphodiesterase Inhibitors to Treat Impotence</i> , Int'l Pub. No. WO 97/03675 (filed on July 11, 1996; published February 6, 1997)
1008	Center for Drug Evaluation and Research, Approval Package for VIAGRA, Approval Date March 27, 1998
1009	<i>Dose-Response Information to Support Drug Registration</i> , 59 FEDERAL REGISTER, (November 9, 1994) 55972-55976
1010	CIALIS® Approved Label, Reference ID: 3820620, Revised September 2015, downloaded from the Food and Drug Administration website <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021368s026lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021368s026lbl.pdf</a> , last accessed November 1, 2016
1011	Eardley, I., <i>New Oral Therapies for the Treatment of Erectile Dysfunction</i> , 81 BR. J. UROL. (1998) 122-127.
1012	Laumann, E.O., <i>et al.</i> , <i>Sexual Dysfunction in the United States</i> , 281 JAMA, (1999) 537-544

1013	Terrett, N.K., <i>et al.</i> , <i>Sildenafil (VIAGRA<sup>TM</sup>), A Potent and Selective Inhibitor of Type 5 cGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction</i> , 6 BIOORG. MED. CHEM. LETT., (1996) 1819-1824
1014	VIAGRA <sup>®</sup> Approved Label, 69-5485-00-2, Revised November 1998, downloaded from the Food and Drug Administration website <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/viagra_label2.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/viagra_label2.pdf</a> , last accessed November 1, 2016
1015	Boolell, M., <i>et al.</i> , <i>Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</i> , 8 INT. J. IMPOT. RES., (1996) 47-52
1016	Licht, M.R., <i>Sildenafil (Viagra) for treating male erectile dysfunction</i> , 65 CLEVE. CLIN. J. MED., (1998) 301-304
1017	Gingell, C. J. C., <i>et al.</i> , <i>A New Oral Treatment for Erectile Dysfunction: A Double-Blind, Placebo-Controlled, Once Daily Dose Response Study</i> , 155 Suppl 5 J. UROL. (1996) Abstract No. 738
1018	Morales, A., <i>et al.</i> , <i>Clinical safety of oral sildenafil citrate (VIAGRA<sup>TM</sup>) in the treatment of erectile dysfunction</i> , 10 INT. J. IMPOT. RES., (1998) 69-74
1019	Cheitlin, M.D., <i>et al.</i> , <i>Use of Sildenafil (Viagra) in Patients with Cardiovascular Disease</i> , 33 J. AM. COLL. CARDIOL. (1999) 273-282
1020	<i>Lilly and ICOS Establish a Joint Venture to Develop and Market PDE5 Compounds to Treat Sexual Dysfunction</i> Eli Lilly and Company PRESS RELEASE 1998 October 1
1021	Norman, P., <i>IC-351 ICOS Corp</i> , 1 CURR. OPIN. CPNS INVEST. DRUGS (1999) 268-271
1022	<i>Reserved</i>
1023	Nies, A.S., <i>Principles of Therapeutics</i> , GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS (Gilman, A. G., <i>et al.</i> , eds., 8 <sup>th</sup> Ed. 1990) 62-83

1024	Oates, J. A. and Wilkinson, G. R., <i>Principles of Drug Therapy</i> , HARRISON'S PRINCIPLES OF INTERNAL MEDICINE (Isselbacher, K. J., et al., eds., 13 <sup>th</sup> Ed. 1994)
1025	Bourne, H. R., and Roberts, J. M., <i>Drug Receptors &amp; Pharmacodynamics</i> , BASIC & CLINICAL PHARMACOLOGY (Katzung, B. G. ed., 6 <sup>th</sup> Ed. 1995) 9-32
1026	Halvorsen, J.G., and Metz, M.E., <i>Sexual Dysfunction, Part I: Classification, Etiology, And Pathogenesis</i> , 5 J. AM. BOARD FAM. PRACT., (1992) 51-61
1027	COLOR ATLAS OF PHARMACOLOGY, (Lüllmann, H., et al., eds., 1993) 44-57
1028	Goldstein, I., et al., <i>Oral Sildenafil in the Treatment of Erectile Dysfunction</i> , 338 N. ENGL. J. MED., (1998) 1397-1404
1029	de Mey, C., <i>Opportunities for the Treatment of Erectile Dysfunction by Modulation of the NO Axis-Alternatives to Sildenafil Citrate</i> , 14 CURR. MED. RES. OPIN., (1998) 187-202
1030	<i>Eli Lilly and Company et al v. Mylan Pharmaceuticals Inc.</i> , No. 1:16-cv-01122 (AJT-MSN)
1031	Drug Approval Package: Viagra (Sildenafil) NDA 020895, Date Created March 27, 1998, downloaded from the Food and Drug Administration website <a href="http://www.accessdata.fda.gov/drugsatfda_docs/NDA/98/viagra/viagra_toc.cfm">http://www.accessdata.fda.gov/drugsatfda_docs/NDA/98/viagra/viagra_toc.cfm</a> , last accessed November 4, 2016
1032	Approval Letter Viagra (Sildenafil) NDA 020895, March 27, 1998.
1033	<i>Drug company's shares rise on FDA approval of pill to treat impotence</i> , CNNMoney.com, March 27, 1998, downloaded from <a href="http://money.cnn.com/1998/03/27/companies/impotence/">http://money.cnn.com/1998/03/27/companies/impotence/</a> , last accessed November 17, 2016
1034	<i>Pfizer's Eagerly Anticipated Impotence Drug Viagra Wins FDA Approval</i> , Dow Jones Online News, March 27, 1998

1035	<i>ICOS Announces Clinical Results and Initiation of Trials</i> ICOS Corporation <i>PRESS RELEASE</i> 1998 September 17
1036	U.S. Provisional Patent Application No. 60/123,244, filed March 8, 1999
1037	Transcript of April 27, 2017 Telephonic Hearing in IPR2017-00323

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.